Literature DB >> 31428419

Health-related quality of life in inflammatory bowel disease in a Danish population-based inception cohort.

Lea K Christiansen1, Bobby Lo1, Flemming Bendtsen1, Ida Vind1, Marianne K Vester-Andersen1,2, Johan Burisch1.   

Abstract

Background: Crohn's disease (CD) and ulcerative colitis (UC) are associated with reduced health-related quality of life (HRQoL), but findings differ between studies. The aim of this study was to analyse the impact of disease activity and social factors on HRQoL. Method: A total of 513 patients diagnosed with UC and CD between 2003 and 2004, in a population-based setting, were followed for 7 years. HRQoL was assessed using the Short Form-12, the Short Inflammatory Bowel Disease (IBD) Questionnaire (SIBDQ), the Work Productivity and Activity Impairment Questionnaire: General Health and a national health survey. Associations were assessed using multiple linear regressions.
Results: A total of 185 of the eligible patients (UC: 107 (50.2%) and CD: 78 (50.3%)) were included. No differences in disease-specific or generic HRQoL were found between CD and UC patients, and IBD patients did not differ compared with the background population. The majority of CD (73.1%) and UC (85.0%) patients had 'good' disease-specific HRQoL using the SIBDQ. Unemployment for ≥ 3 months occurred more in CD vs UC patients(30.6 vs 15.5%, p = 0.03); however, sick leave for ≥ 3 months did not differ significantly (17.4 vs 11.4%, p = 0.4). Using multiple linear regressions, unemployment, sick leave and disease activity were the factors most frequently associated with reduced HRQoL.
Conclusion: In a population-based cohort with 7 years of follow-up, HRQoL did not differ between patients and the background population.

Entities:  

Keywords:  Crohn's disease; Inflammatory bowel disease; cohort study; observational study; patient-reported outcome; quality of life; ulcerative colitis

Mesh:

Year:  2019        PMID: 31428419      PMCID: PMC6683643          DOI: 10.1177/2050640619852532

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  42 in total

Review 1.  A review of health-related workplace productivity loss instruments.

Authors:  Jennifer H Lofland; Laura Pizzi; Kevin D Frick
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database.

Authors:  Ida Vind; Lene Riis; Tine Jess; Elisabeth Knudsen; Natalia Pedersen; Margarita Elkjaer; Inger Bak Andersen; Vibeke Wewer; Peter Nørregaard; Flemming Moesgaard; Flemming Bendtsen; Pia Munkholm
Journal:  Am J Gastroenterol       Date:  2006-06       Impact factor: 10.864

3.  Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis.

Authors:  Tomm Bernklev; Jørgen Jahnsen; Tom Schulz; Jostein Sauar; Idar Lygren; Magne Henriksen; Njål Stray; Øystein Kjellevold; Erling Aadland; Morten Vatn; Bjørn Moum
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-10       Impact factor: 2.566

4.  Absenteeism due to Functional Limitations Caused by Seven Common Chronic Diseases in US Workers.

Authors:  Tam D Vuong; Feifei Wei; Claudia J Beverly
Journal:  J Occup Environ Med       Date:  2015-07       Impact factor: 2.162

5.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

Review 6.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

Review 7.  Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease.

Authors:  Nicolas Williet; William J Sandborn; Laurent Peyrin-Biroulet
Journal:  Clin Gastroenterol Hepatol       Date:  2014-02-15       Impact factor: 11.382

8.  Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort.

Authors:  Johan Burisch; Ryan Ungaro; Ida Vind; Michelle V Prosberg; Flemming Bendtsen; Jean-Frederic Colombel; Marianne K Vester-Andersen
Journal:  J Crohns Colitis       Date:  2017-10-01       Impact factor: 9.071

9.  Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health.

Authors:  Laurent Peyrin-Biroulet; Alarcos Cieza; William J Sandborn; Michaela Coenen; Yehuda Chowers; Toshifumi Hibi; Nenad Kostanjsek; Gerold Stucki; Jean-Frédéric Colombel
Journal:  Gut       Date:  2011-06-05       Impact factor: 23.059

10.  Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis.

Authors:  Gert Huppertz-Hauss; Marte Lie Høivik; Ebbe Langholz; Selwyn Odes; Milada Småstuen; Reinhold Stockbrugger; Geir Hoff; Bjørn Moum; Tomm Bernklev
Journal:  Inflamm Bowel Dis       Date:  2015-02       Impact factor: 5.325

View more
  5 in total

1.  Work and School Absenteeism in Inflammatory Bowel Disease Patients in Jeddah, Saudi Arabia: A Cross-Sectional Study.

Authors:  Mahmoud H Mosli; Abdullah A Alamri; Omar I Saadah
Journal:  Saudi J Med Med Sci       Date:  2021-04-29

2.  Work Productivity Loss in Inflammatory Bowel Disease Patients in Turkey.

Authors:  Firdevs Topal; Hakan Camyar; Elif Saritas Yuksel; Suleyman Gunay; Fatih Topal; Emine Özlem Gür
Journal:  Gastroenterol Res Pract       Date:  2020-01-08       Impact factor: 2.260

3.  Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study.

Authors:  Talat Bessissow; Geoffrey C Nguyen; Osman Tarabain; Laurent Peyrin-Biroulet; Nathalie Foucault; Kevin McHugh; Joannie Ruel
Journal:  World J Gastroenterol       Date:  2022-09-14       Impact factor: 5.374

4.  Infliximab for Crohn's Disease Patients with Perianal Fistulas: Better Image, Better Life.

Authors:  Liwen Hong; Chen Zhang; Rong Fan; Lei Wang; Zhengting Wang; Tianyu Zhang; Jie Zhong
Journal:  Med Sci Monit       Date:  2020-08-12

5.  Quality of Life in Newly Diagnosed Moderate-to-Severe Ulcerative Colitis: Changes in the MOSAIK Cohort Over 1 Year.

Authors:  Ik Hyun Jo; Kang-Moon Lee; Dae Bum Kim; Ji Won Kim; Jun Lee; Yoon Tae Jeen; Tae-Oh Kim; Joo Sung Kim; Jae Jun Park; Sung Noh Hong; Dong Il Park; Hyun-Soo Kim; Yoo Jin Lee; Youngdoe Kim
Journal:  Gut Liver       Date:  2022-05-15       Impact factor: 4.519

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.